A Stable Switch From Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/FTC/TAF) to Dolutegravir/Lamivudine (DTG/3TC) in the Absence of Historical Resistance Records: Results From the Switch to Dovato in Patients Suppressed on Biktarvy (SOUND) Cohort
Results from SOUND support the efficacy and safety of switching to DTG/3TC for people living with HIV-1 who are virologically suppressed on B/FTC/TAF with unknown resistance history and may confer a weight advantage.
Authors
- Paul Bellafiore
- James Fallon
- Masara Touza (ORCID: https://orcid.org/0000-0003-1796-6939)
- Jihad Slim (ORCID: https://orcid.org/0000-0002-4192-7246)
- Rebecca A Borsi
Institutions
- Saint Michael's Medical Center (US)
Publication Details
- Journal
- Cureus
- Published
- 2025-04-21
- DOI
- https://doi.org/10.7759/cureus.82716
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00